Exelixis earnings on deck: Can RCC franchise weather competition?

Exelixis is expected to report Q1 EPS of $0.77 on revenue of $608.95 million, implying 24% EPS growth and 10% revenue growth year over year, but EPS is down sequentially from $0.97 in Q4. Investors are focused on CABOMETYX franchise durability amid intense RCC competition and the August 2026 patent expiry, while zanzalintinib remains a key pipeline catalyst with an FDA decision due Dec. 3, 2026. The setup is mixed: modest upward EPS estimate revisions and a buy-rated stock with about 8% implied upside are offset by revenue estimate declines and patent-cliff risk.

Analysis

EXEL is still being priced as a durable single-franchise compounder, but the market is underestimating how quickly patent-risk narratives can compress multiples before the actual LOE date. In biotech, valuation often de-rates 6-12 months ahead of exclusivity loss; that means the stock can start discounting a post-CABOMETYX earnings cliff well before the August 2026 expiry, especially if management signals only incremental diversification.

The key second-order issue is competitive elasticity in RCC: even if CABOMETYX holds share, combo-therapy incumbents can cap pricing power and reset growth expectations without causing an immediate volume collapse. That creates a subtle but important asymmetry — the downside path is a slow grind lower on multiple compression and estimate drift, while the upside requires visible evidence that zanzalintinib can become a meaningful second engine well before the LOE window closes.

The contrarian angle is that near-term numbers may be good enough to keep shorts uncomfortable, but not good enough to re-rate the stock materially higher. If management uses the upcoming print to frame 2026 as a true catalyst-rich inflection rather than a bridge year, the stock could squeeze on complacent positioning; if not, the combination of modest estimate revisions and a looming patent overhang makes this look more like a fade-the-rally name than a clean long.

Net: this is a classic "good business, bad stock setup" into an aging patent curve, with the decisive variable being whether pipeline optionality is advancing fast enough to offset multiple compression before the market forces the issue.

Key Decisions for Investors

• Maintain a tactical short bias in EXEL over the next 3-6 months via put spreads or stock short into strength; target a 10-15% downside if RCC growth decelerates or guidance sounds cautious, with limited fundamental downside if the name has already started to de-rate.
• If long EXEL, use it only as a catalyst trade into data/FDA milestones, not a core hold; trim or hedge once the market starts pricing 2026 patent expiry into forward estimates, likely 2-4 quarters before LOE.
• Pair trade: long a diversified oncology platform with multiple late-stage shots on goal, short EXEL, to isolate pipeline-duration risk versus single-franchise concentration; this expresses the view that EXEL’s earnings quality will deteriorate faster than peers.
• For event-driven accounts, buy short-dated calls only on evidence of upside surprise in revenue mix or zanzalintinib-related commentary; otherwise avoid chasing the print since the skew favors a sell-the-news response.
• Set a catalyst calendar around the next 2 quarters: if estimate revisions stay flat while revenue growth decelerates, increase short exposure; if zanzalintinib progress materially accelerates, cover into the rerating window.